June MIMS update

A look at some of the recent changes to the medicines landscape, with new products and indications New Products Avacopan (Tavneos) is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between C5aR1 and the anaphylatoxin C5a. The specific and selective blockade of C5aR1 by avacopan reduces